Basit öğe kaydını göster

dc.contributor.authorSunar, Veli
dc.contributor.authorKorkmaz, Vakkas
dc.contributor.authorArik, Zafer
dc.contributor.authorOzdal, Bulent
dc.contributor.authorEngin Ustun, Yaprak
dc.date.accessioned2021-06-03T05:19:55Z
dc.date.available2021-06-03T05:19:55Z
dc.date.issued2019
dc.identifier.issn1306-133X
dc.identifier.urihttp://dx.doi.org/10.4999/uhod.193783
dc.identifier.urihttp://hdl.handle.net/11655/23942
dc.description.abstractThis study aims to analyze the clinicopathologic characteristics and treatment outcomes of our patients with gestational trophoblastic neoplasia (GTN) and to present our real-life experience. A total of 32 patients with GTN diagnosed according to the FIGO 2002 criteria followed in Zekai Tahir Burak Women's Health Training and Research Hospital between 2011-2018 were included. Demographic features, treatment outcomes, and survival were analyzed retrospectively. The median follow up time was 32.1 (3.3-76.9) months. Of the 32 patients, 27 (84.4%) were defined as low-risk GTN (risk score < 7) and 5 (15.6%) were high-risk GTN (risk score >= 7) according to the FIGO risk score. Seventeen (62.9%) patients with low-risk GTN achieved complete remission (CR) with single agent MTX. CR rate was 60% (12/20) in patients receiving weekly MTX and 71.4% (5/7) in MTX-FA eight-day regimen (p= 0.590). Of the 9 MTX resistant patients, 8 (88.8%) achieved CR with second-line Actinomycin D (ActD). Three (60%) out of the five high-risk GTN patients acquired CR with first-line EMA-CO (etoposide, MTX, plus ActD alternating with cyclophosphamide and vincristine). In the follow-up period one patient (3.1%) had recurrent disease. By the data cut off date, all of the patients were alive and CR could not be achieved in one (3.1%) patient. All patients with low-risk GM achieved CR with sequential therapies ultimately. Therefore, single agent MTX is a reasonable option in the initial treatment of low-risk GTN. Moreover, Actinomycin D is highly effective in patients with low-risk GTN who are resistant to MTX.
dc.language.isoen
dc.relation.isversionof10.4999/uhod.193783
dc.rightsAttribution 4.0 United States
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectactinomycin D
dc.subjectEMA-CO protocol
dc.subjectGestational Trophoblastic Neoplasia
dc.subjectMethotrexate
dc.subjectTrophoblastic Disease
dc.titleRetrospective Analysis Of Gestational Trophoblastic Neoplasia: Single Center Experience
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalUhod-Uluslararasi Hematoloji-Onkoloji Dergisi
dc.contributor.departmentİç Hastalıkları
dc.identifier.volume29
dc.identifier.issue3
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

Attribution 4.0 United States
Aksi belirtilmediği sürece bu öğenin lisansı: Attribution 4.0 United States